Bioventus Inc.
BVS · NASDAQ
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -6.1% | 19.2% | -19.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 67% | 69.1% | 67% | 66.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 8.7% | 12.4% | 3.9% | 5.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 2.3% | 5.1% | -2.1% | -0.1% |
| EPS | 0.047 | 0.11 | -0.04 | -0.002 |
| % Growth | -57.2% | 375% | -1,900% | – |
| EPS Diluted | 0.046 | 0.11 | -0.04 | -0.002 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 16% | 20.2% | 12.9% | 14.1% |